Bioactivity:

JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy.

CAS nr:

669076-03-3

Purity:

98%

Molecular Weight:

490,64

SMILES:

O=C(O)C[C@H](CC1CCN(C(CCC2=CC=C3CCCN=C3N2)=O)CC1)[C@H]4CNC5=C(C=CC=C5)C4

Formula:

C29H38N4O3

Pathway:

Target: